Search clinical trials for: Estrogen receptor positive (ER )
Total 29686 results
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast Cancer | Arthralgia | Hot Flashes | Sexual Dysfunction | Musculoskeletal ComplicationsUnited States, Puerto Rico
-
European Organisation for Research and Treatment...Sanofi; Novartis; Roche Pharma AG; Breast International Group; AgendiaCompleted
-
SOLTI Breast Cancer Research GroupPfizerCompleted
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
-
Seoul National University HospitalActive, not recruitingInvasive Breast Cancer | Estrogen Receptor Positive Breast CancerKorea, Republic of
-
The Netherlands Cancer InstituteGenentech, Inc.; EurocanPlatform; RatherCompletedBreast CancerSpain, Netherlands, France, United Kingdom
-
National Cancer Institute (NCI)CompletedRecurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Progesterone Receptor Positive | Stage IIIC Breast Cancer AJCC v6 | Stage IV Breast Cancer AJCC v6 and v7United States, Puerto Rico
-
Jonsson Comprehensive Cancer CenterBayer; Translational Research in Oncology-U.S. Inc. (TRIO-US)TerminatedStage I Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative and other conditionsUnited States
-
Dana-Farber Cancer InstitutePfizerCompletedHuman Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone Receptor (HR)-Positive Breast CancerUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.; Translational Breast Cancer... and other collaboratorsTerminatedStage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast CarcinomaUnited States
-
Stemline Therapeutics, Inc.CompletedAdvanced ER+, HER2-Negative Breast CancerUnited States
-
Queen Mary University of LondonHoffmann-La Roche; Asan Medical Center; Kliniken Essen-Mitte; MedSIRActive, not recruitingBreast Cancer | Estrogen Receptor-positive Breast CancerUnited Kingdom
-
Velindre NHS TrustAstraZeneca; Cardiff and Vale University Health Board; Covance; Cenduit LLCActive, not recruitingEstrogen Receptor Positive Breast CancerUnited Kingdom
-
Dana-Farber Cancer InstituteNovartisCompleted
-
Case Comprehensive Cancer CenterCompleted
-
PfizerCompletedBreast CancerAustralia, India
-
Celcuity, Inc.Completed
-
Novartis PharmaceuticalsGlaxoSmithKlineCompletedNeoplasms, BreastBelgium, United Kingdom, Croatia, Hungary, Argentina, Australia, Germany, Israel, Japan, Poland, Russian Federation, Spain, France, Korea, Republic of, Hong Kong, United States, Brazil, Bulgaria, China, India, Ireland, Italy, Philip... and more
-
Syndax PharmaceuticalsCompleted
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
Hoffmann-La RocheCompletedEarly Breast CancerSpain, Korea, Republic of, Australia, Taiwan, Ukraine, Poland, Russian Federation, United States, Germany, Brazil, Hungary
-
H. Lee Moffitt Cancer Center and Research InstituteAstraZenecaTerminatedBreast Cancer | Hormone Receptor Positive TumorUnited States
-
Northwestern UniversityNational Cancer Institute (NCI); MedImmune LLC; Avon Breast Cancer FoundationCompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu NegativeUnited States
-
Syndax PharmaceuticalsCompletedBreast Cancer | ER+ Breast Cancer | Estrogen Receptor-Positive Breast Cancer | Breast Cancer, Estrogen Receptor-PositiveUnited States, Czechia, Canada, Hungary, Russian Federation
-
NSABP Foundation IncPfizer; Genomic Health®, Inc.CompletedBreast CancerUnited States, Canada
-
NSABP Foundation IncNational Cancer Institute (NCI)Active, not recruitingBreast CancerUnited States, Puerto Rico
-
Emory UniversityNovartisTerminatedStage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast CancerUnited States
-
Dana-Farber Cancer InstituteNovartisTerminatedMetastatic Hormone-Receptor-Positive (HR+) Breast Cancer | HER2-Negative Breast Cancer | Metastatic Epithelial Ovarian CancerUnited States
-
Novartis PharmaceuticalsCompletedColorectal Cancer, Triple Negative Breast Cancer, NSCLC - AdenocarcinomaUnited States, France, Taiwan, Canada, Italy, Singapore, Belgium, Spain, Israel
-
Sun Yat-sen UniversityCompletedBreast Cancer MetastaticChina
-
PfizerCompletedBreast NeoplasmsSpain, Korea, Republic of, United States, Australia, Italy, Russian Federation
-
University of California, San FranciscoDana-Farber Cancer Institute; Translational Breast Cancer Research ConsortiumCompletedMetastatic Breast Cancer | Hormone Receptor PositiveUnited States
-
University of Colorado, DenverCompletedBreast Cancer | Stage II Breast Cancer | Stage III Breast CancerUnited States
-
Memorial Sloan Kettering Cancer CenterNovartis PharmaceuticalsCompletedMetastatic or Locally-advanced Unresectable Breast CancerUnited States
-
Institut Claudius RegaudTerminated
-
Boehringer IngelheimCompletedNeoplasmsSpain, Korea, Republic of, Belgium, Taiwan, United Kingdom, Austria, France, Netherlands, Ireland, Sweden
-
H. Lee Moffitt Cancer Center and Research InstituteNovartisCompletedBreast Cancer | Breast Cancer - Female | Breast Cancer - MaleUnited States
-
NSABP Foundation IncRoyal Marsden NHS Foundation Trust; Pfizer; Institute of Cancer Research, United...CompletedBreast Cancer | Breast Tumors | Breast CarcinomaUnited Kingdom, United States, Canada
-
Palleos Healthcare GmbHPfizer; Cankado GmbH; WSG WOMEN´S HEALTHCARE STUDY GROUP; AGO-TraFo; AGO-B; Deutsche...Terminated
-
Syndax PharmaceuticalsCompletedBreast Cancer | Estrogen Receptor Positive Breast CancerUnited States
-
University of VirginiaWithdrawnBreast Cancer | Estrogen Receptor-positive Breast CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Recurrent Uterine Corpus Carcinoma | Estrogen Receptor Positive | PostmenopausalUnited States
-
Washington University School of MedicineWithdrawn
-
Novartis PharmaceuticalsCompleted
-
ETOP IBCSG Partners FoundationCompletedBreast CancerSpain, Switzerland, Hungary, France, Italy, Peru, Portugal, Sweden
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingHER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7United States
-
Novartis PharmaceuticalsCompletedAdvanced Metastatic Breast CancerGermany
-
Novartis PharmaceuticalsCompletedBreast CancerUnited States
-
Georgetown UniversityUniversity of Chicago; Thomas Jefferson UniversityCompletedHormone Receptor Positive HER-2 Negative Breast CancerUnited States
-
The Methodist Hospital Research InstituteMillennium Pharmaceuticals, Inc.CompletedEstrogen Receptor Positive Breast CancerUnited States